Ariad Pharmaceuticals Inc fka ARIA

[glass_half_full]

Hey there, Don -- thanks. If I have time later, I may try to dig around for the dasa-/nilotonib approval timeline.

You comment actually brings up another question that I had:

There was a fair amount of buzz about the '534 trial being designed to produce data that would support skipping phase 2.

At the conference, a presenter mentioned a "pivotal" trial this year, but I recall somewhere else mention of phase 2 for '534.

Should I mentally file this with the Rida 2nd interim report -- i.e., positive, but not what shorter-horizon investors were hoping for?

Thx